KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Retained Earnings: 2011-2025

Historic Retained Earnings for Sarepta Therapeutics (SRPT) over the last 14 years, with Sep 2025 value amounting to -$4.6 billion.

  • Sarepta Therapeutics' Retained Earnings fell 6.21% to -$4.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.6 billion, marking a year-over-year decrease of 6.21%. This contributed to the annual value of -$4.2 billion for FY2024, which is 5.29% up from last year.
  • Latest data reveals that Sarepta Therapeutics reported Retained Earnings of -$4.6 billion as of Q3 2025, which was down 4.03% from -$4.5 billion recorded in Q2 2025.
  • Sarepta Therapeutics' 5-year Retained Earnings high stood at -$3.0 billion for Q1 2021, and its period low was -$4.7 billion during Q1 2025.
  • Over the past 3 years, Sarepta Therapeutics' median Retained Earnings value was -$4.4 billion (recorded in 2023), while the average stood at -$4.5 billion.
  • As far as peak fluctuations go, Sarepta Therapeutics' Retained Earnings tumbled by 33.67% in 2023, and later increased by 5.29% in 2024.
  • Sarepta Therapeutics' Retained Earnings (Quarterly) stood at -$3.2 billion in 2021, then fell by 21.94% to -$3.9 billion in 2022, then declined by 13.71% to -$4.4 billion in 2023, then increased by 5.29% to -$4.2 billion in 2024, then decreased by 6.21% to -$4.6 billion in 2025.
  • Its last three reported values are -$4.6 billion in Q3 2025, -$4.5 billion for Q2 2025, and -$4.7 billion during Q1 2025.